Free Trial
NASDAQ:LFCR

Lifecore Biomedical Q1 2026 Earnings Report

Lifecore Biomedical logo
$7.53 -0.41 (-5.16%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$7.54 +0.01 (+0.20%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lifecore Biomedical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Lifecore Biomedical Revenue Results

Actual Revenue
N/A
Expected Revenue
$26.68 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lifecore Biomedical Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, October 3, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Lifecore Biomedical Earnings Headlines

Analysts Offer Predictions for LFCR Q1 Earnings
KeyCorp Begins Coverage on Lifecore Biomedical (NASDAQ:LFCR)
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
See More Lifecore Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lifecore Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lifecore Biomedical and other key companies, straight to your email.

About Lifecore Biomedical

Lifecore Biomedical (NASDAQ:LFCR) is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care. Lifecore supplies sterile injectable HA solutions used in viscoelastic applications for cataract and other eye surgeries, viscosupplementation for joint disorders and HA gels for soft-tissue augmentation and dermal therapies. In addition, its research and development team works on advanced cross-linking technologies to improve product longevity and biocompatibility.

Beyond its own branded offerings, Lifecore provides contract development and manufacturing services to global customers in the pharmaceutical, medical device and aesthetic industries. Its FDA-registered, GMP-compliant facility in Minnesota supports process development, scale-up and commercial production of HA and related biopolymers. Lifecore’s integrated services enable partners to accelerate time-to-market for novel formulations and medical devices.

Founded in 1993, Lifecore has grown from a single-product developer to a diversified HA specialist serving markets in North America, Europe and Asia. The company is led by President and Chief Executive Officer Erin Tagge, who has more than 20 years of experience in biopharmaceutical development and manufacturing. Under her leadership, Lifecore continues to invest in quality systems, research collaborations and facility expansions to support long-term growth.

View Lifecore Biomedical Profile

More Earnings Resources from MarketBeat